Abstract
Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Graphical Abstract
Current Drug Safety
Title:Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum
Volume: 12 Issue: 2
Author(s): Upinder Kaur, Sankha Shubhra Chakrabarti, Rohit Singh and Indrajeet Singh Gambhir*
Affiliation:
- Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 221005, UP,India
Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Abstract: Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Export Options
About this article
Cite this article as:
Kaur Upinder, Chakrabarti Shubhra Sankha, Singh Rohit and Gambhir Singh Indrajeet*, Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170518153225
DOI https://dx.doi.org/10.2174/1574886312666170518153225 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal
Duration
Current Pharmaceutical Design Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Editorial (Hot Topic: Cardiovascular Disease Biomarkers: from Tradition to Modernity)
Current Topics in Medicinal Chemistry Stroke Prevention in Atrial Fibrillation: Concepts and Controversies
Current Cardiology Reviews Obesity, Hypertension and Hypercholesterolemia as Risk Factors for Atherosclerosis Leading to Ischemic Events
Current Medicinal Chemistry Pharmacogenetics of Oral Anticoagulant Therapy
Current Pharmaceutical Design Recent Research Developments in the Direct Inhibition of Coagulation Proteinases – Inhibitors of the Initiation Phase
Cardiovascular & Hematological Agents in Medicinal Chemistry Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Osteoarthritis - An Update
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women
Current Vascular Pharmacology Evaluation of Two Recombinant Plasminogen Activators in Massive Pulmonary Embolism Model and Potato Carboxypeptidase Inhibitor (PCI) role in Inhibition of Thrombin Activatable Fibrinolysis Inhibitor TAFIa in Lungs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Treatment Strategies for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Timing of Drug Administration for Thromboprophylaxis Following Orthopaedic Surgery: Evidence and Controversies Related to Treatment Initiation and Duration
Current Vascular Pharmacology